This is particularly pertinent to patients with advanced prostate cancer, who are currently treated with hormone-deprivation therapies (ADT) and/or drugs interfering with either the transcriptional activity of the androgen receptor (AR), referred to as (ARIs), or the synthesis of androgens. This evidence concerns the gene AR and prostate carcinoma.